

# Our Impact in 2024



T1International





**T1International**

*Our Impact in 2024*

A Word from Our Executive Director	03
Our Approach and Values	04
Our Work	05
How We Work	05
Global Highlights	06
USA Highlights	07
What We Do	08
Key Moments	09
Global Day of Action for #insulin4all	09
A T1International Toast	10
South Africa Action for Insulin Pens	11
Keeping Up the Pressure in the United States	12
Our Year in Numbers	13
Our Team	14
Thanks to Funders and Partners	15
Our Finances	16
USA Finances	16
Global Finances	17

# A Word from Our Executive Director



Dear friends and colleagues,

As I begin my role as the new Executive Director at T1International, I want to share my story and thank everyone who has made this work possible.

I didn't choose to focus on insulin access and affordability – it chose me. My sister and I both have type 1 diabetes, and we've experienced firsthand the power that pharmaceutical companies hold over our lives. My career as a grassroots organizer began in housing and environmental justice, but after my diagnosis, I found myself relying on the very same structures of corporate greed.

Everything changed when I heard Liz, T1International's founder, speak about T1International's 2019 protest against Eli Lilly. I realized that T1International wasn't just a group of people living with diabetes – it was a global community challenging Big Pharma and fighting effectively for affordable insulin and care. I knew I had to get involved.

T1International has grown from a small organization into a global force for #insulin4all. We are mobilizing networks, taking strategic action, and winning meaningful policy changes to make insulin and diabetes care accessible to all. Over the past few years, I've seen our work make progress holding corporations accountable and fighting for a world where insulin is a basic human right. And we still have a long way to go to build the people power we need to win real, long-lasting global change.

I am deeply grateful to Liz and the T1International community for building this movement and to everyone who has shared their story, taken action, and supported this fight. Together, we'll ensure no one with diabetes is held hostage by corporate greed.

Thank you for standing with us.

With gratitude,  
Shaina Kasper

A handwritten signature in black ink, appearing to read 'Shaina Kasper'.

T1International is a non-profit led by people with and impacted by type 1 diabetes, for people with type 1 diabetes. We believe that where you are born should not determine whether you live or die from diabetes. However, one out of every two people in need of insulin cannot access or afford it. We bring experiences and voices of patients to the forefront of local and global health agendas to create sustainable, long-term change.

## Our Vision

We believe in a world where everyone with type 1 diabetes – no matter where they live – has everything they need to survive and achieve their dreams.

## Our Mission

We support local communities by giving them the tools they need to stand up for their rights so that access to insulin and diabetes supplies becomes a reality for all.

## Our Values

T1International's values of being patient-led, independent, transparent, inclusive, bold, and hopeful serve to inspire us and hold us accountable alongside our action plans.



Photo • Advocates from around the globe meet virtually to strategize for #insulin4all.

# How We Work

At T1International, we are committed to achieving #insulin4all. Our mission is to drive systemic, lasting change by **empowering strong local groups** worldwide to achieve campaign and policy objectives tailored to their specific local context. Together, we **run targeted and strategic advocacy campaigns** for insulin access and affordability. Through specialized training, goal setting, and strategic action planning tailored to local political realities, we equip advocates with the tools they need to make a difference.

Our movement thrives on **building strong and supporting connections and collaborations** through mentoring, advice, and peer-to-peer learning. These networks amplify our collective efforts, turning individual campaign successes into a shared roadmap for change. By fostering connections within our expert community, we enable #insulin4all Advocates to learn, collaborate, and grow stronger together. Together, we amplify our voices by engaging policymakers, sharing crucial data, and testifying to the realities faced by those who depend on insulin.

We lead the global conversation on insulin affordability, holding firm to the principle of "nothing about us without us." We promote **leadership among those most impacted**, centering the lived experiences of those most affected by the insulin crisis and elevating their stories in the media, research, and advocacy spaces. At T1International, we stand with patients, not Big Pharma, building grassroots leadership and fostering a strong, united community dedicated to winning #insulin4all.



Photos • Advocates and T1International Partners connect at a conference in Tanzania (left and upper right) and at a drug pricing event at the White House (lower right)

# Global Advocacy Network Highlights

T1International's Global Advocacy Network is made up of Global Advocates, Global Advocacy Chapters, and Global Advocacy Partners in more than 20 countries worldwide. Together, we advocate for the rights of people living with diabetes all around the world, including our Fight for Five Campaign.

- **Global Advocates**
- **Global Chapters**
- **Global Advocacy Partners**


In **Gaza**, a humanitarian checkpoint was opened amid calls for a ceasefire, medical envoy, and sustained medical aid. MENA #insulin4all Chapter Leader Mohammed and Advocate Cyrine amplified these urgent needs, speaking at several key global events.

Meethi Zindagi, our Global Advocacy Partner in **Pakistan** achieved their first locally manufactured insulin and implemented an *Insulin for All* program for free insulin delivery for children with type 1 diabetes.

The new **Nigeria** #insulin4all Chapter petitioned and took action for a tax that would fund non-communicable disease support, including insulin.

In **South Africa**, T1International and Médecins Sans Frontières led a petition calling on insulin manufacturers to lower the cost of insulin pens to \$1, and to demand that insulin pens not be discontinued in the country.

Help Madina and We Care Sierra Leone, our Global Advocacy Partners in **Sierra Leone**, established a Diabetes Care Unit at Makeni Regional Hospital, supporting people without government or private aid. They created a documentary on Makeni's challenges and held screenings using solar-powered cinema kits.



# USA Advocacy Network Highlights

The USA Advocacy Network is made up of Advocates, Chapters, and Advocacy Partners in all 50 states fighting for #insulin4all.



**Connecticut's** #insulin4all Chapter, T1International, and Yale's Global Health Justice Partnership hosted a discussion with over 120 community members and decision makers about public pharma as an alternative to the current, profit-driven pharmaceutical system.

In solidarity with Advocates in South Africa, the **Washington** #insulin4all Chapter held a protest outside Novo Nordisk offices on World Diabetes Day.

Eli Lilly and Sanofi settled their **Minnesota** lawsuit, agreeing to provide \$35 insulin for 5 years.

**Colorado** updated their Kevin's Law to add more compliance standards and fines for emergency record keeping and manufacturer requirements.

**Florida** updated their Kevin's Law so that people are eligible three times a year for insulin and related supplies.

**Colorado** and **Pennsylvania** now have non-medical switching regulations.

**West Virginia, Washington, Oregon, Minnesota, New York**, and elsewhere updated their copay cap legislation.

# What We Do

## Access to Affordable Insulin:

Insulin was first used to treat a person with diabetes in 1922. The discoverers sold the patent for \$1 each so it could be accessible for all. However, one in two people who need insulin cannot access it because it is inaccessible, unaffordable, or both. We're trying to change that.

- Through our **Fight for Five** campaign, our network is advocating globally for a world where the cost of insulin and glucose testing supplies represents no more than 5% of a person's income in any given country. We initially focused on Panama, Pakistan, India, and Zimbabwe.
- Our **price cap** campaign fights to cap the price of insulin at the pharmacy counter for anyone who needs it, regardless of insurance. This will save lives as we work on more structural changes to lower the cost of insulin.



## Fighting Big Pharma's Monopoly Power:

Eli Lilly, Novo Nordisk, and Sanofi, the 'Big Three' insulin manufacturers, dominate more than 90% of the world insulin market by value. They have way too much power and influence, and they fund academics and advocacy organizations which means very few people or entities challenge them. We are one of the few.

- The high price of insulin is a result of systemic issues in the pharmaceutical industry, including patent abuse and monopolistic practices. While these challenges are significant, our **public pharmaceutical** and **patent reform** campaigns offer hope for a more equitable future. Prioritizing patient needs over corporate profits can make essential medicines like insulin accessible and affordable for all.

## Equitable Health Access for All:

Too many people and places get left behind while diabetes treatments and technologies continue to improve. We believe everyone should have access to the treatment and tools that work best for their body. Through education and research initiatives like our bi-annual Out of Pocket Expenses survey, we're creating more equitable diabetes and care worldwide.

Photo • Indiana #insulin4all advocates protest outside of Eli Lilly's Headquarters on the Global Day of Action for #insulin4all.



# Global Day of Action for #insulin4all



On March 16, 2024, hundreds of #insulin4all Advocates united for the Global Day of Action, holding over a dozen events worldwide to demand insulin equity.

In Zimbabwe, Advocates submitted a letter to the new government, while Tanzania's media campaign highlighted insulin affordability. In Boston, Advocates marched against Big Pharma, carrying insulin vials honoring loved ones. In Paris, Diabète et Méchant delivered a petition urging Sanofi to lower prices globally, with similar petitions targeting Eli Lilly in Indiana and Novo Nordisk in Denmark.

In Islamabad, Meethi Zindagi hosted a roundtable with decision-makers on insulin shortages. New Delhi's Diabetes Fighters Trust performed an #insulin4all dance and submitted letters to officials. Advocates in Indianapolis and Washington, DC, demanded action from Eli Lilly and Congress on insulin pricing.

Online, participants revealed their lifetime insulin costs and the opportunities lost. The message resonated globally: insulin is a human right, not a luxury.

# A T1International Toast




After more than a decade of leadership, our Founder and former Executive Director Elizabeth 'Liz' Pfiester transitioned from her role at T1International, passing the torch (or in our case, megaphone!) to the new Executive Director, Shaina Kasper. To mark the transition, we hosted a T1International Toast, a heartfelt celebration honoring Liz's remarkable legacy and our vibrant #insulin4all community!

This special event showcased the incredible impact made by our global community in a relatively short time, through inspiring stories from Advocates and Advocacy Partners, as well as fun giveaways. Together, we reflected on Liz's contributions, celebrated our collective achievements, and looked ahead to the exciting future of T1International.

By all metrics, the event was a success, welcoming over 130 attendees from around the world, featuring 17 speakers and raising over \$30,000 for the next chapter of our fight for insulin equity.

*"Founding and leading T1International for the past decade has been an incredible journey. I am immensely proud of what we have accomplished together as a community. I am deeply appreciative of the stories and insights shared by our global diabetes community regarding the impact that T1International has had on their lives. And I am confident that the organization will continue to be a powerful patient-led movement under Shaina's capable leadership. There is so much more work to be done."*

- Elizabeth 'Liz' Pfiester



# South Africa Action for Insulin Pens



On World Diabetes Day, T1International highlighted a global injustice: millions in low- and middle-income countries lack access to affordable insulin pens, a critical diabetes management tool. Despite being preferred by 82% of people for their accuracy, ease of use, and reduced stigma, insulin pens remain inaccessible due to monopolistic practices by pharmaceutical giants Eli Lilly, Novo Nordisk, and Sanofi.

Novo Nordisk's decision to halt insulin pen distribution in South Africa has worsened this crisis, forcing many to revert to vials and syringes, increasing risks of complications and emotional strain. Novo plans to phase out human insulin pen production globally, while prioritizing expensive

treatments for wealthier markets, deepening inequality.

In Johannesburg, T1International and Advocacy Partners Médecins Sans Frontières Access Campaign, Treatment Action Campaign (TAC), and Santé Diabète picketed Novo Nordisk, delivering a petition demanding insulin pens be priced at \$1. Research shows this price is still profitable.

Additionally, T1International submitted a proposal to the World Health Organization to include rapid-acting insulin on the Essential Medicines List, a step toward equitable insulin access worldwide. Public consultations are forthcoming, calling advocates to join the fight against profiteering in diabetes care.

Photo • Advocate Janice takes action for #insulin4all in Johannesburg, South Africa on World Diabetes Day.

# Keeping Up the Pressure in the United States



The year brought implementation to many of the policies that T1International has spent years working on: Prices for Novolog and Fiasp vials and pens have dropped over 75% for Medicare beneficiaries. T1International team members were invited to the White House and to Congress six times over the course of the year – it is clear that T1International and patient advocates are making historic progress.

However, there's still work to be done. These insulins cost only a few dollars to produce, yet prices in the United States remain double double the UK's NHS negotiated price. Additionally, 150,000 Medicare beneficiaries are excluded by the \$35 monthly insulin copay cap, and many private insurance holders and uninsured individuals remain unprotected. T1International continues to push for fair pricing of all insulins and essential medicines for everyone.

Our advocacy extends to urging Health and Human Services to address the discontinuation of long-acting insulin Levemir. We continue to demand that the government take action to stop this and ensure that no one is left without access to life-saving medications.

Photos • Advocate James meets with former United States Vice President Harris; Advocate Tracy shares her story at the White House; Advocate Lina speaks outside the United States Capitol on the Global Day of Action for #insulin4all; and Advocate Kevin attends as Representative Jayapal's guest for the State of the Union.

## Our Year In Numbers

We welcomed **7** new #insulin4all Chapter Leaders and **3** Advocacy Partners.

Our Global Advocacy Network spanned **23** countries.

After **2.5** years of running our Fight for Five campaign, the World Health Organization published the global monitoring framework for diabetes prevention and control metrics.

We delivered over **1,000** petition signatures to Eli Lilly calling on them to adopt a human rights policy at the Annual General Meeting of shareholders. Ultimately, we got **10%** of the vote.

In South Africa, T1International called on insulin manufacturers to lower the cost of insulin pens to **\$1** and to demand that insulin pens not be discontinued alongside Médecins Sans Frontières Access Campaign, Treatment Action Campaign (TAC), and Santé Diabète.

T1International #insulin4all Advocates were in over **100** media in at least **8** countries.

T1International submitted a formal proposal to add **3** rapid-acting insulins to the World Health Organization's Model List.

**18** Advocates graduated from our inaugural Speakers Bureau class.

**3000** people, particularly in low- and middle-income countries, had their voices heard on World Diabetes Day to lower insulin prices.

# 13

on-the-ground actions held with T1International #insulin4all Chapters and Advocacy Partners around the world

# 1373

signatures on our World Diabetes Day petition delivered to Novo Nordisk in South Africa

# 3437

#insulin4all Advocates took action across the globe

# \$100

million from the Novo Nordisk Foundation was accepted by the World Health Organization, prompting T1International to send a letter condemning the conflict of interest

# Our Team

T1International is a registered charity in England and Wales and T1International USA is a registered 501(c)(3) organisation based in the United States. In September 2024, we made the strategic decision to close our U.K. entity. This allows us to focus our resources on expanding global programs, enhancing support for patient leaders, and eliminating duplicative administrative efforts. By streamlining our operations, we are better positioned to invest in impactful initiatives and strengthen the global #insulin4all movement.

Additionally, we were thrilled to complete our board recruitment process, selecting four new Trustees to join the board in 2025. Their participation supports our long-term strategic goal to ensure T1International's board is made up of a majority of people with significant lived experience in the Global South. You can read more about our current team and Board of Trustees on our website.



Photos • T1International staff team members take joy in meeting in person in the United States and United Kingdom

# Thanks to Funders and Partners

We deeply appreciate every supporter of T1International, regardless of the size of their contribution. Our work is essential, and it comes with costs—but we remain steadfast in our commitment to never accept funding from Big Pharma. That’s why the backing of passionate individuals is crucial to sustaining our independent, impactful advocacy. Despite the challenges we face, we are unwavering in our mission. As we continue to embrace transitions and change, we will boldly demonstrate our community’s power and resilience.

*Thank you to all of our Global G1vers, whose steadfast regular support empowers our team in a sustainable, ongoing way.*

## Our Funders

Anonymous  
Arnold Ventures  
Economic Securities Project  
Joffe Charitable Trust  
McPike-Zima Foundation  
Red Sox Foundation



At T1International, we believe that by working together we can make a bigger impact in the lives of people living with diabetes than if we were only working as individual organisations. Partners work together with T1International on projects or programs, and we act with mutual recognition and allyship on our collective goals.

## Our Partners

Analysis Group (USA)  
Diabète et Méchant (France)  
Diabet Centro (Guatemala)  
Diabetes Consciousness for Community (Tanzania)  
Diabetes Fighters Trust (India)  
Diabetes LATAM (Panama)  
Diabetes Youth Care (Ghana)  
Generation Patient (USA)  
Help Madina (Sierra Leone)  
Médecins Sans Frontières Access Campaign  
Meethi Zindagi (Pakistan)  
Santé Diabète (Mali)  
Science, Health, and Information Clinic (USA)  
We Care Sierra Leone (Sierra Leone)

# USA Finances

Our USA finances relate to funds raised, managed, and spent through T1International USA, a tax-exempt organisation (EIN: 84-2544817) under section 501(c)(3) of the United States Internal Revenue Code.



Over the past year, we have worked on investing in our highest performing income streams sources, growing individual fundraising efforts, and optimizing our budgets for long-term sustainability. While our expenditures in 2024 exceeded the funds we raised, we were able to utilize surplus reserves from previous years. In addition to the income below, we received \$219,959 in remaining funds from the from the U.K. entity following its closure.

## USA Income

A. Grants	\$191,008
B. Individuals	\$125,798
C. Corporates and Community	\$30,171
<hr/>	
	<b>\$346,977</b>

## USA Expenditure

D. Direct Programme Costs	\$273,556
E. Core Staff Costs	\$92,339
F. Operational Costs	\$34,605
<hr/>	
	<b>\$458,557</b>





# Global Finances

Our global finances relate to funds raised, managed, and spent through T1International based in the UK, Charity Commission registration number 1168249.

In 2024, we prioritized investing in our global community of advocates, diversifying our income streams, and refining our budgets, while finalizing the decision to close the U.K. entity in September and subsequently redirecting fundraising efforts to the U.S. entity.

## Global Income

A. Grants	£185,403
B. Individuals	£13,769
C. Corporates and Community	£ 17,523
<hr/>	
	<b>£216,696</b>

## Global Expenditure

D. Direct Programme Costs	£28,250
E. Core Staff Costs	£138,582
F. Operational Costs	£6,411
<hr/>	
	<b>£173,243</b>







Photo • Advocates take action outside Eli Lilly headquarters in Indianapolis, Indiana.

If you have any questions or want to find out how you can get involved, please reach out to us at: [contact@t1international.com](mailto:contact@t1international.com).

To make a donation or become a sustaining Global G1ver today, visit: [t1international.com/donate](https://t1international.com/donate).

T1International is a registered charitable incorporated organisation (CIO) in England and Wales (1168249).

T1International USA is a tax-exempt organisation (EIN: 84-2544817) under section 501(c)(3) of the United States Internal Revenue Code.